• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by 10x Genomics Inc.

    6/6/24 4:13:23 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email
    DEFA14A 1 txg-2024defa14a.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ______________________
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    ______________________
    Filed by the RegistrantxFiled by a Party other than the Registranto
    Check the appropriate box:
    oPreliminary Proxy Statement
    oConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    oDefinitive Proxy Statement
    xDefinitive Additional Materials
    oSoliciting Material Pursuant to §240.14a-12
    10x Genomics, Inc.
    (Name of Registrant as Specified In Its Charter)
    Payment of Filing Fee (Check the appropriate box):
    xNo fee required.
    oFee paid previously with preliminary materials.
    oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i) and 0-11




    [Form of email communication sent to certain investors in advance of the 2024 Annual Meeting of Stockholders]

    From: Eric S. Whitaker, Chief Legal Officer

    Subject: 10x Genomics

    I’m contacting you again this year to support the company’s proposals. One is a little unusual so I wanted to raise it to your attention.

    As you know, we are seeking a change to our bylaws as part of our annual meeting process. Currently, amendments to certain portions of 10x’s bylaws require approval by two-thirds of shareholders in addition to Board approval. Proposal 3 would amend the bylaws to allow the Board to change 10x’s bylaws without the need for a shareholder vote.

    This provision appears to be an artifact of our time as a private company and came to our attention when we recently considered an amendment to the bylaws to conform to the new shareholder-friendly SEC rules opening Company-sponsored proxy cards to all duly-nominated director candidates from all parties including shareholder nominated candidates (so called “universal proxy” rules). We were not able to make this change because of the supermajority shareholder requirement to amend the bylaws. Absent approval of the currently proposed bylaws amendment, such a routine, administrative matter as updating the bylaws to facilitate “universal proxy” cards would require a shareholder vote (and accompanying solicitation campaign).

    As you likely know, Glass Lewis supports the proposed amendment which would bring us in line with 98.1% of all Russell 3000 companies. As Glass Lewis said in its recommendation in support of our proposal:

    In this case, we acknowledge that the governing documents of the vast majority of public companies permit their boards of directors to adopt, amend and repeal the bylaws of such companies. While we believe the board should seek shareholder ratification of bylaw amendments that significantly impact shareholder rights (and may recommend against directors if the board does not), we do not believe this caveat is sufficient grounds to deprive the board of what is generally recognized as a basic authority of a board. We note, as per Delaware law, shareholders will continue to have the right to adopt, amend or repeal the Company's bylaws through the affirmative vote of two-thirds of shares outstanding. All this being the case, we believe shareholders can reasonably support this proposal. [emphasis added]

    We have researched this issue and have identified only nine historical instances in which a public company has had a supermajority shareholder voting requirement to approve a Board-approved change to bylaws. We are an extreme outlier on this issue.

    We are asking for your support for the following reasons:

    1.It would allow 10x to flexibly and efficiently comply with changes to Delaware and other applicable law and rules.

    •Changes to Delaware law or SEC and Nasdaq rules and regulations periodically necessitate updates to 10x’s bylaws to remain in compliance.
    •Recent examples of common changes to public company bylaws include changes related to “universal proxy” cards (discussed above), the timing and form of stockholder meeting notices, the ability to use “a captive insurer” for D&O indemnification, requirements related to making stockholder lists available in connection with annual meetings, the ability to hold virtual meetings (a COVID-19 era change), forum selection clauses and proxy access.
    •Such changes to the bylaws are all quite administrative in nature and not worthy of a shareholder vote - which is, again, why 98% of public companies delegate these matters to the Board.

    2.It reduces administrative burdens on the company, saves costs, and allows management and the Board to focus on strategic matters.

    •Seeking shareholder approval – even when a proposal has broad shareholder support – incurs meaningful financial and time commitments by 10x’s Board, and management.
    •Reducing the need for frequent shareholder votes on bylaw amendments lowers the administrative burden and costs associated with holding special meetings or including proposals in annual meetings.




    We have heard certain shareholder concerns and want to address them directly.

    First, we have heard a concern that it will reduce shareholder influence on the company. That concern should be mitigated by the following:

    •Shareholders exercise their influence through the election of directors. If a Board implements amendments that negatively impact shareholder rights, the accepted approach - followed by more than 98% of public companies - is to vote against the directors.
    •Even if the resolution passes, shareholders will still retain their ability to amend the bylaws as noted by Glass Lewis and as enshrined in Delaware law.
    •For the vast majority of public companies, the Board’s ability to amend bylaws without a shareholder vote is, according to Glass Lewis, “generally recognized as a basic authority of a board.”

    Second, we heard concerns that even though shareholders would retain the right to put an amendment to the bylaws to a vote, the supermajority required in that instance is effectively negated by the remaining high-vote 10x shares. This concern was raised by ISS. However, it is mitigated by the following:

    •The power to elect directors who shareholders determine are best equipped to represent their interests - a right which rests solely with our shareholders - is commonly thought to be the best check against that. Of course, it only takes a majority vote to elect a director.
    •Delaware law also imposes limits on board actions through its rules around fiduciary duties including the duty of care and loyalty.

    Finally, we have been asked whether we have any plans to amend the bylaws beyond the current proposal.

    •We view the proposed change as a housekeeping measure to facilitate routine, administrative bylaws amendments to respond to routine legal and regulatory changes.
    •If this proposal is approved, the only plan we currently have to amend our bylaws would be to add new shareholder protections stemming from the “universal proxy” card rules recently approved by the SEC and discussed above.

    We appreciate your consideration of this request and would be more than willing to answer any questions you have.


    Best,


    Eric S. Whitaker
    Chief Legal Officer






    Get the next $TXG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    12/11/2025Buy → Neutral
    Citigroup
    12/2/2025$20.00Overweight → Equal-Weight
    Morgan Stanley
    9/11/2025$15.00Neutral
    Piper Sandler
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $TXG
    SEC Filings

    View All

    10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - 10x Genomics, Inc. (0001770787) (Filer)

    1/12/26 3:52:51 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

    SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    1/8/26 9:27:57 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

    SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    11/13/25 9:02:42 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    1/22/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

    Study aims to identify single cell immune signatures of disease activity and treatment response to support clinical care PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a world-class academic medical center, to analyze peripheral blood samples from patients living with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and giant cell arteritis (GCA) to uncover immune signatures associated with disease activity, flare, remission and therapeutic response.

    1/12/26 9:11:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling

    Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology 10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progressi

    1/12/26 9:10:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saxonov Serge exercised 50,000 shares at a strike of $1.20, increasing direct ownership by 5% to 1,071,556 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    1/7/26 4:52:55 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Taich Adam sold $225,852 worth of shares (11,888 units at $19.00), decreasing direct ownership by 4% to 297,385 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    11/25/25 5:24:48 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Hindson Benjamin J. sold $157,363 worth of shares (8,283 units at $19.00), decreasing direct ownership by 2% to 432,605 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    11/25/25 5:24:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/25 5:22:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    10x Genomics downgraded by Citigroup

    Citigroup downgraded 10x Genomics from Buy to Neutral

    12/11/25 8:24:15 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded 10x Genomics from Overweight to Equal-Weight and set a new price target of $20.00

    12/2/25 8:22:39 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Piper Sandler initiated coverage on 10x Genomics with a new price target

    Piper Sandler initiated coverage of 10x Genomics with a rating of Neutral and set a new price target of $15.00

    9/11/25 8:40:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    View All

    10x Genomics Announces Senior Leadership Changes

    PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

    8/8/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care

    ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

    Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

    1/10/22 8:00:00 AM ET
    $RARE
    $TXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Financials

    Live finance-specific insights

    View All

    10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    1/22/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics Reports Third Quarter 2025 Financial Results

    PLEASANTON, Calif., Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025. Recent Updates Revenue was $149.0 million for the third quarter, compared to $172.9 million in the second quarter, which included $27.3 million related to one-time license and royalty revenue. Third quarter revenue represents a 2% increase sequentially, excluding the second quarter one-time license and royalty revenue.Started shipping the next-generation of Chromium Flex,

    11/6/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025

    PLEASANTON, Calif., Oct. 9, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    10/9/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/8/24 2:46:37 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/5/24 6:07:26 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

    SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

    10/4/24 2:14:32 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials